Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.69 |
| ▸ | CTSS | P25774 | 4/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 4/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105463 | 1.00 | CTSK (0.69) | CTSKCTSSCA2KDM4EALDH1A1 | |
| SCHEMBL3757938 | 0.88 | CTSS (0.69) | CTSKCTSSCA2KDM4EALDH1A1 | |
| SCHEMBL1918997 | 0.88 | CTSS (0.69) | CTSKCTSSCA2KDM4EALDH1A1 | |
| SCHEMBL1918995 | 0.88 | CTSS (0.69) | CTSKCTSSCA2KDM4EALDH1A1 | |
| SCHEMBL10210703 | 0.87 | CTSS (0.67) | CTSKCTSSCA2KDM4EALDH1A1 | |
| SCHEMBL5730481 | 0.87 | CTSS (0.67) | CTSKCTSSCA2KDM4EALDH1A1 | |
| SCHEMBL29147405 | 0.87 | CTSS (0.67) | CTSKCTSSCA2KDM4EALDH1A1 | |
| SCHEMBL18793329 | 0.87 | CTSS (0.67) | CTSKCTSSCA2KDM4EALDH1A1 | |
| SCHEMBL15081482 | 0.84 | CTSK (0.64) | CTSKCTSSCA2KDM4EALDH1A1 | |
| SCHEMBL8203738 | 0.84 | CTSK (0.64) | CTSKCTSSCA2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516063-B2 | Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives for treating autoimmune diseases | ELI LILLY AND COMPANY (US) | 2026-01-06 | — | — | US | disclosed |
| CN-115038705-B | 7- (Methylamino) pyrazolo [1,5-a ] pyrimidine-3-carboxamide compounds | 伊莱利利公司 | 2024-11-08 | — | — | CN | disclosed |
| US-12060356-B2 | 7 (methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives | ELI LILLY AND COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4103279-B1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | LILLY CO ELI (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-4103565-B1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | LILLY CO ELI (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11891400-B2 | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus | ELI LILLY AND COMPANY (US) | 2024-02-06 | — | — | US | disclosed |
| CN-115052660-B | Substituted 7- (methylamino) pyrazolo [1,5-a ] pyrimidine-3-carboxamide derivatives | 伊莱利利公司 | 2024-01-09 | — | — | CN | disclosed |
| US-20230136885-A1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY | 2023-05-04 | — | — | US | disclosed |
| US-20230136885-A1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY | 2023-05-04 | — | — | US | disclosed |
| US-20230136885-A1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY | 2023-05-04 | — | — | US | disclosed |
| US-20210253581-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | ELI LILLY AND COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-20210253581-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | ELI LILLY AND COMPANY | 2021-08-19 | — | — | US | disclosed |
| WO-2021162944-A1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021162942-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2021-08-19 | — | — | WO | disclosed |
| CN-113166163-A | 7- (methylamino) pyrazolo [1,5-A ] pyrimidine-3-carboxamide derivatives | 伊莱利利公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210188861-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY | 2021-06-24 | — | — | US | disclosed |
| US-20210188861-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY | 2021-06-24 | — | — | US | disclosed |
| CN-112638915-A | Pyrazolo [1,5-a ] pyrimidine-3-carboxamide derivatives for the treatment of psoriasis and systemic lupus erythematosus | 伊莱利利公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020123225-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020055636-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | ELI LILLY AND COMPANY (US) | 2020-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060356-B2 | 7 (methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives | SSB, TLR7, TPMT | CTSK 1785/4885CTSS 3688/4885CA2 1703/4885 |
| US-11891400-B2 | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus | SSB, TPMT, SPHK1 | CTSK 1351/4885CTSS 2806/4885CA2 2108/4885 |
| US-20210188861-A1 | PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSORIASIS AND SYSTEMIC LUPUS ERYTHEMATOSUS | SSB, TPMT, SPHK1 | CTSK 1351/4885CTSS 2806/4885CA2 2108/4885 |
| US-20210253581-A1 | 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS | SSB, IL1R1, SLC5A1 | CTSK 2429/4885CTSS 3766/4885CA2 2335/4885 |
| US-20230136885-A1 | SUBSTITUTED 7-(METHYLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE DERIVATIVES | SSB, IL1R1, SLC5A1 | CTSK 2500/4885CTSS 3519/4885CA2 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.